36,872 Shares in CG Oncology, Inc. (NASDAQ:CGON) Bought by Monashee Investment Management LLC

Monashee Investment Management LLC acquired a new position in CG Oncology, Inc. (NASDAQ:CGON - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 36,872 shares of the company's stock, valued at approximately $1,057,000.

A number of other institutional investors have also recently bought and sold shares of CGON. Foresite Capital Management VI LLC bought a new stake in CG Oncology in the fourth quarter worth about $63,712,000. Marshall Wace LLP increased its stake in shares of CG Oncology by 18,836.0% during the 4th quarter. Marshall Wace LLP now owns 1,458,072 shares of the company's stock worth $41,818,000 after purchasing an additional 1,450,372 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of CG Oncology by 274.4% in the 4th quarter. Wellington Management Group LLP now owns 1,910,470 shares of the company's stock worth $54,792,000 after purchasing an additional 1,400,251 shares during the period. Decheng Capital LLC lifted its stake in CG Oncology by 16.3% in the fourth quarter. Decheng Capital LLC now owns 6,371,669 shares of the company's stock valued at $182,739,000 after purchasing an additional 892,859 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in CG Oncology by 15.3% during the fourth quarter. Vanguard Group Inc. now owns 5,861,082 shares of the company's stock valued at $168,096,000 after purchasing an additional 779,730 shares during the period. Institutional investors own 26.56% of the company's stock.

Analyst Ratings Changes

CGON has been the topic of several research reports. Scotiabank assumed coverage on CG Oncology in a research note on Wednesday, April 16th. They issued a "sector perform" rating and a $23.00 target price on the stock. Morgan Stanley restated an "overweight" rating and issued a $55.00 price objective on shares of CG Oncology in a research note on Friday, March 7th. HC Wainwright reiterated a "buy" rating and set a $75.00 target price on shares of CG Oncology in a research report on Monday. TD Cowen initiated coverage on shares of CG Oncology in a research note on Tuesday, January 7th. They issued a "buy" rating for the company. Finally, Royal Bank of Canada upped their price target on shares of CG Oncology from $66.00 to $68.00 and gave the company an "outperform" rating in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $59.56.

Insider Activity

In related news, Director Leonard E. Post sold 1,000 shares of the company's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $30.76, for a total value of $30,760.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

CG Oncology Price Performance

NASDAQ CGON opened at $26.94 on Wednesday. The company's 50 day simple moving average is $23.60 and its two-hundred day simple moving average is $29.15. The stock has a market capitalization of $2.05 billion, a PE ratio of -18.97 and a beta of 1.24. CG Oncology, Inc. has a 1 year low of $14.80 and a 1 year high of $46.99.

CG Oncology (NASDAQ:CGON - Get Free Report) last posted its quarterly earnings data on Tuesday, March 25th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.11). CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. The business had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.11 million. On average, research analysts anticipate that CG Oncology, Inc. will post -1.31 EPS for the current year.

CG Oncology Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.